Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders
- Author(s)
- Thompson, PA; Tam, CS;
- Details
- Publication Year 2023-06-29,Volume 141,Issue #26,Page 3137-3142
- Journal Title
- Blood
- Publication Type
- Review
- Abstract
- Patients with lymphoproliferative disorders such as chronic lymphocytic leukemia and mantle cell lymphoma (MCL) who are resistant to covalent Bruton tyrosine kinase inhibitors (cBTKis), especially if also venetoclax refractory, have an unmet therapeutic need. Pirtobrutinib, a noncovalent BTKi, achieves high response rates in patients who are refractory to cBTKi, regardless of mechanism of cBTKi resistance. This led to recent accelerated US Food and Drug Administration approval in MCL. The toxicity profile in early studies suggests suitability for use in combination approaches. We summarize existing preclinical and clinical data for pirtobrutinib.
- Publisher
- American Society of Hematology
- Keywords
- Humans; *Antineoplastic Agents/pharmacology/therapeutic use; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; *Lymphoma, Mantle-Cell/drug therapy/pathology; *Lymphoproliferative Disorders/drug therapy; Protein Kinase Inhibitors/therapeutic use/pharmacology
- Department(s)
- Clinical Haematology
- PubMed ID
- 37156004
- Publisher's Version
- https://doi.org/10.1182/blood.2023020240
- Open Access at Publisher's Site
https://doi.org/10.1182/blood.2023020240- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-10-12 07:16:43
Last Modified: 2023-10-12 07:16:59